Lung Cancer Trials

Alliance A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).

Alliance A081105 - Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo In Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC). (Must first enroll in ALLIANCE A151216 to be eligible).

ECOG-ACRIN E4512 - A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. (Must first enroll in ALLIANCE A151216 to be eligible).

ECOG-ACRIN EA5142 - Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers. (Must first enroll in ALLIANCE A151216 to be eligible).